Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 ...

As the U.S. stock market takes a breather after a significant post-election rally, investors are assessing their portfolios amid heightened optimism and fluctuating indices. In this context, penny ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

While one answer is to work harder and learn through repeated trial and error, that’s not a guarantee, and it means running ...

We continue to be well capitalized with an anticipated cash runway into the first half of 2027 and are ... We are a clinical-stage precision oncology company singularly focused on discovering, ...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...

Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

Once a utilitarian brand known for its reliability, Stanley has leveraged the power of collaborations to stay fresh and ...